bosentan anhydrous has been researched along with Disease Models, Animal in 99 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (17.17) | 18.2507 |
| 2000's | 39 (39.39) | 29.6817 |
| 2010's | 37 (37.37) | 24.3611 |
| 2020's | 6 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Bolli, MH; Boss, C; Clozel, M; Fischli, W; Hess, P; Weller, T | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, D; Chen, Y; Du, G; Fang, L; Niu, Z; Yuan, T; Zhang, H | 1 |
| Hojná, S; Kadlecová, M; Kompanowska-Jezierska, E; Vaněčková, I; Zicha, J | 1 |
| Bir, F; Enli, Y; Ergin, H; Özdemir, ÖM; Şahin, B; Taban, Ö | 1 |
| Bai, J; Fan, X; Hu, J; Hu, M; Li, Y; Sun, Y; Wang, B; Xu, Y; Zhao, S | 1 |
| Furue, M; Kido-Nakahara, M; Nakahara, T; Ohno, F; Takemura, M; Tsuji, G; Ulzii, D; Wang, B | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Akita, K; Isobe, S; Isoda, K; Iwakura, Y; Minamino, T; Niida, T; Ohtomo, F; Sano, M; Sato-Okabayashi, Y; Shimada, K | 1 |
| Andrews, MC; Arozarena, I; Brunton, H; Cooper, ZA; Dummer, R; Ferguson, J; Flaherty, KT; Frederick, DT; Haass, NK; Kmarashev, J; Levesque, MP; McEntegart, S; Miskolczi, Z; Rodriguez, J; Rowling, EJ; Sloss, O; Smith, MP; Spoerri, L; von Kriegsheim, A; Wargo, JA; Wellbrock, C | 1 |
| Bağrıaçık, EÜ; Dileköz, E; Ercan, S; Karaca, EE; Kul, O; Or, M; Öztürk Fincan, GS; Uzun, F | 1 |
| Acco, A; Chichorro, JG; Dos Reis, RC; Gambeta, E; King, T; Kopruszinski, CM; Rae, GA | 1 |
| Das, S; Laha, B; Maiti, S; Sen, KK | 1 |
| Jian, X; Wang, J; Zhang, W; Zhang, Z; Zhou, Q | 1 |
| Dong, Q; Gong, S; He, X; Lv, J; Peng, L; Seng, Z; Wang, W; Yan, B | 2 |
| Bortolamiol, C; Bossu, A; Clozel, M; Hess, P; Iglarz, M; Rey, M; Wanner, D | 1 |
| Ceribasi, AO; Demir, T; Dokuyucu, R; Kaplan, DS; Kisacik, B; Koc, I; Onat, AM; Orkmez, M; Pehlivan, Y; Taysi, S; Turkbeyler, IH; Tutar, E | 1 |
| Akamata, K; Aozasa, N; Asano, Y; Ichimura, Y; Noda, S; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T | 1 |
| Fontoura, D; Leite, S; Leite-Moreira, AF; Lourenço, AP; Mendes-Ferreira, P; Oliveira-Pinto, J; Tavares-Silva, M; Vasques-Nóvoa, F | 1 |
| Akpinar, E; Altuner, D; Atmaca, HT; Bayraktutan, Z; Cakici, O; Ekinci, M; Halici, Z; Keles, S; Yayla, M; Yildirim, K | 1 |
| Braine, CE; Howell, GR; John, SW; Macalinao, DG; MacNicoll, KH; Soto, I; Sousa, GL | 1 |
| Akpinar, E; Aksakal, AM; Atmaca, HT; Aydin, A; Cadirci, E; Halici, Z; Karcioglu, SS; Kunak, CS; Saritemur, M; Yayla, M | 1 |
| Buyukakilli, B; Citirik, D; Gurgul, S; Hallioglu, O; Ozeren, M; Tasdelen, B | 1 |
| Day, JS; Guan, Y; Guo, Y; Hillgren, KM; Michie, SA; Nishimura, S; Nishimura, T; Peltz, G; Takeda, ST; Wu, M; Xu, D; Yang, Z; Yates, AJ; Zheng, M | 1 |
| Gómez-Meda, BC; Lemus-Varela, Mde L; Melnikov, V; Ornelas-Aguirre, JM; Soliz, A; Torres-Mendoza, BM; Zamora-Perez, AL; Zúñiga-González, GM | 1 |
| Abman, SH; Acker, SN; Gien, J; Kuhn, K; Nozik-Grayck, E; Partrick, DA; Seedorf, GJ | 1 |
| Chilakapati, DR; Chilakapati, SR; Kanala, JR; Serasanambati, M; Vissavajjhala, P | 1 |
| Asano, Y | 1 |
| Bauer, Y; Bortolamiol, C; Cattaneo, C; Clozel, M; Delahaye, S; Freti, D; Hadana, H; Hess, P; Iglarz, M; Landskroner, K; Nayler, O; Renault, B; Rey, M; Schläpfer, M; Steiner, P; Studer, R; Vercauteren, M; Vezzali, E; Wanner, D; Weber, E; Whitby, BR | 1 |
| Halici, Z; Kose, D; Polat, E; Tatar, A; Yayla, M; Yoruk, O | 1 |
| Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Lin, TY; Wang, SS | 1 |
| Favre, J; Henry, JP; Lallemand, F; Marie, I; Richard, V; Solans, V; Thuillez, C | 1 |
| Arner, A; Dou, Y; Garmaroudi, FS; Hegele, RG; Laher, I; Luo, H; Luo, Z; Marchant, D; McDonough, JE; McManus, BM; Si, X; Walker, E | 1 |
| He, JG; Tan, XY | 1 |
| Belaidi, E; Godin-Ribuot, D; Joyeux-Faure, M; Launois, SH; Levy, P; Ribuot, C | 1 |
| Canning, P; Degooyer, TE; Kelso, EJ; Lee, GR; McDermott, BJ; McDonald, D; McDonald, L; Stitt, AW | 1 |
| Arzt, M; Blumberg, F; Nüchterlein, M; Pfeifer, M; Schroll, S; Sebah, D | 1 |
| Barcelos, LS; Camargos, ER; Chiari, E; Machado, CR; Rachid, MA; Tanowitz, HB; Teixeira, AL; Teixeira, MM | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Chen, CC; Hsu, YJ; Lee, TM; Lien, HY; Lin, CC; Shih, CM | 1 |
| Caldwell, E; de Frutos, S; Gonzalez Bosc, LV; Kanagy, NL; Nitta, CH; Walker, MK; Wang, J; Wang, W | 1 |
| Dupuis, J; Jiang, BH; Shi, Y; Tardif, JC | 1 |
| Cavasin, MA; Chapo, J; Peng, Y; Pitts, K; Plato, CF; Sandoval, J; Semus, H | 1 |
| de Man, FS; Handoko, ML; Vonk-Noordegraaf, A | 1 |
| Barbay, JM; Barres, BA; Clark, AF; Hibbs, M; Howell, GR; John, SW; King, BL; Kneeland, SC; Libby, RT; Macalinao, DG; Marchant, JK; Soto, I; Sousa, GL; Stevens, B; Walden, M | 1 |
| Choudhary, G; Harrington, EO; Klinger, JR; Martin, D; Troncales, F | 1 |
| Bräuer, R; Gajda, M; Glück, L; Imhof, AK; Schaible, HG; Schulz, S | 1 |
| Aggarwal, S; Black, SM; Jonigk, D; Kumar, S; Rafikov, R; Rafikova, O; Schneider, F; Sharma, S; Tofovic, SP | 1 |
| Guimarães, CL; Rae, GA; Trentin, PG | 1 |
| Begin, KJ; Gorga, JA; Kihara, Y; LeWinter, MM; Noguchi, T; Palmiter, KA; VanBuren, P | 1 |
| Dumont, AS; Dumont, RJ; Kassell, NF; McNeill, JH; Sutherland, GR; Verma, S | 1 |
| Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM | 1 |
| Goto, K; Miyauchi, T | 1 |
| Abdel Kafi, S; Bejjani, G; Biarent, D; Hubloue, I; Leeman, M; Mélot, C; Naeije, R | 1 |
| Alfonso, F; Aragoncillo, P; Escaned, J; Fantidis, P; Fernández-Durango, R; Fernández-Ortiz, A; Hernández, R; Macaya, C; Rollín, R; Sanmartín, M | 1 |
| Inagaki, K; Iwanaga, Y; Izumi, T; Kihara, Y; Kita, T; Noma, A; Onozawa, Y; Sarai, N; Takenaka, H; Yoneda, T | 1 |
| Guc, MO; Iskit, AB; Senel, I; Sokmensuer, C | 1 |
| Bonetti, PO; Elesber, AA; Lerman, A; Lerman, LO; Woodrum, JE; Younkin, SG; Zhu, XY | 1 |
| Anthoni, C; Krieglstein, CF; Laukötter, MG; Mennigen, RB; Rijcken, EJ; Schürmann, G; Senninger, N; Spiegel, HU | 1 |
| Chen, YP; Dong, HR; Qiu, CB; Zhang, C | 1 |
| Fujimoto, K; Ikenoya, S | 1 |
| Clemens, MG; Karaa, A; Keller, S; Paxian, M; Zhang, JX | 1 |
| Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR | 1 |
| Aslaner, A; Deniz, M; Ghandour, S; Günal, O | 1 |
| Binkert, C; Clozel, M; Hess, P; Iglarz, M; Qiu, C; Rey, M | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Barcellos, L; Camargos, ER; Chiari, E; Huang, H; Machado, CR; Marques, CA; Rachid, MA; Tanowitz, HB; Teixeira, MM | 1 |
| Barcelos, LS; Machado, CR; Machado, PP; Mariano, FS; Roffê, E; Romanha, AJ; Silva, JS; Souza, AL; Tanowitz, HB; Teixeira, MM | 1 |
| Chang, NC; Lee, TM; Lin, MS | 1 |
| Deveci, F; Gamze, K; Ilhan, F; Mehmet, HM; Ozercan, I; Turgut, T | 1 |
| Chang, NC; Chen, CC; Lee, TM; Lin, MS | 1 |
| Beuzard, Y; Bonnin, P; Castier, Y; de Franceschi, L; Debbabi, H; Dussaule, JC; Galaup, A; Germain, S; Girot, R; Henri, A; Janin, A; Leboeuf, C; Levy, B; Maier-Redelsperger, M; Malpeli, G; Sabaa, N; Scarpa, A; Tharaux, PL; Vandermeersch, S | 1 |
| Akpolat, N; Ayten, R; Bulbuller, N; Cetinkaya, Z; Kirkil, C; Ustundag, B | 1 |
| Stevens, EJ; Tomlinson, DR | 1 |
| Filep, JG; Földes-Filep, E; Fournier, A | 1 |
| Clozel, JP; Clozel, M; Gray, GA; Löffler, BM; Roux, S; Sprecher, U | 1 |
| Benati, L; Benigni, A; Corna, D; Facchinetti, D; Orisio, S; Remuzzi, G; Zola, C | 1 |
| Egido, J; Gómez-Garre, D; Gutierrez, S; Largo, R; Liu, XH; López-Armada, MJ; Palacios, I | 1 |
| Collins, SM; Hogaboam, CM; Hunt, RH; Muller, MJ | 1 |
| Abassi, Z; Better, OS; Gurbanov, K; Hoffman, A; Rubinstein, I; Winaver, J | 1 |
| Herizi, A; Jover, B; Mimran, A | 1 |
| Bauer, C; Braun, C; Braun, N; Hocher, B; Koppenhagen, K; Neumayer, HH; Rohmeiss, P; Schwarz, A; Thöne-Reineke, C; Vogt, V; Zart, R | 1 |
| Charlier, AA; Donckier, JE; Heyndrickx, GR; Hodeige, DG; Ketelslegers, JM; Massart, PE; Van Mechelen, H | 1 |
| D'Orléans-Juste, P; De-Melo, JD; Rae, GA; Tonussi, CR | 1 |
| Schiffrin, EL | 1 |
| Best, PJ; Hasdai, D; Holmes, DR; Lerman, A; McKenna, CJ | 1 |
| Hvaal, K; Mathisen, SR; Nordsletten, L; Skjeldal, S; Svindland, A | 1 |
| Fraser, TB; Mangos, GJ; Turner, SW; Whitworth, JA | 1 |
| Furukawa, Y; Matsumori, A; Ono, K; Sasayama, S; Shioi, T | 1 |
| Karasawa, F; Sato, T; Tanaka, K | 1 |
| Christen, S; Ferriero, DM; Leib, SL; Pfister, LA; Shaw, S; Täuber, MG; Tureen, JH | 1 |
| Channick, RN; Chiles, PG; Kim, H; Konopka, RG; Marsh, JJ; Morris, TA; Pedersen, CA; Yung, GL | 1 |
| Chen, YF; Oparil, S | 1 |
| Guc, MO; Iskit, AB | 1 |
| Löffler, BM; Spiegel, HU; Uhlmann, D; Uhlmann, S; Witzigmann, H | 1 |
| Chen, J; Gu, Y; Lin, F; Lin, S; Yang, H; Zhu, C; Zhu, W | 1 |
| Attramadal, H; Clausen, OP; Grøgaard, HK; Oie, E; Yndestad, A; ØIje, E | 1 |
| Belloni, AS; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rossi, GP; Sartore, S | 1 |
6 review(s) available for bosentan anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelial Cells; Epigenesis, Genetic; Fibroblasts; Genetic Predisposition to Disease; Humans; Macrophages; Mice; Mice, Transgenic; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Sulfonamides; Th17 Cells; Th2 Cells | 2015 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
[New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
Topics: Animals; Bosentan; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Growth Substances; Humans; Mitogens; Receptors, Endothelin; Sulfonamides; Vasoconstriction | 2003 |
[Pharmacological characteristics and clinical efficacy of bosentan].
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; In Vitro Techniques; Nitric Oxide Synthase; Randomized Controlled Trials as Topic; Sulfonamides; Vasoconstriction | 2005 |
Endothelin and endothelin antagonists in hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular System; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Sulfonamides | 1998 |
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
93 other study(ies) available for bosentan anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; CHO Cells; Cricetinae; Disease Models, Animal; Drug Monitoring; Endothelin Receptor Antagonists; Heart Rate; Hypertension; Inhibitory Concentration 50; Pyrimidines; Rats; Rats, Inbred Dahl; Structure-Activity Relationship; Sulfonamides | 2003 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertension, Pulmonary; Indazoles; Male; Monocrotaline; Nitriles; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilator Agents | 2022 |
Distinct effects of bosentan on NO-dependent vasodilation and calcium influx in heterozygous Ren-2 transgenic rats on high-salt diet.
Topics: Animals; Blood Pressure; Bosentan; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Endothelin Receptor Antagonists; Heterozygote; Hypertension; Male; Nitric Oxide; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Sodium Chloride, Dietary; Vasodilation | 2019 |
The effects of bosentan on hyperoxia-induced lung injury in neonatal rats.
Topics: Actins; Animals; Animals, Newborn; Biomarkers; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Hyperoxia; Immunohistochemistry; Injections, Intraperitoneal; Lung; Lung Injury; Rats; Rats, Wistar; Treatment Outcome | 2019 |
Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects.
Topics: Animals; Bosentan; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Flavonoids; Food-Drug Interactions; HEK293 Cells; Herb-Drug Interactions; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Methotrexate; Molecular Conformation; Organic Anion Transporters; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan.
Topics: Animals; Bosentan; Dermatitis, Atopic; Disease Models, Animal; Endothelin Receptor Antagonists; Mice; Mites; Pruritus; Skin | 2021 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Blocking of interleukin-1 suppresses angiotensin II-induced renal injury.
Topics: Angiotensin II; Animals; Antibodies; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Humans; Hypertension; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Kidney; Kidney Diseases; Mice, Inbred C57BL; Mice, Knockout; Signal Transduction | 2021 |
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Topics: Animals; Antineoplastic Agents; Bosentan; Cell Line, Tumor; Disease Models, Animal; Endothelin Receptor Antagonists; Heterografts; Humans; Melanoma; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Zebrafish | 2017 |
The effect of endothelin receptor antagonists in the endotoxin-induced uveitis rabbit model
Topics: Animals; Aqueous Humor; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Eye; Eye Proteins; Intravitreal Injections; Leukocyte Count; Lipopolysaccharides; Male; Peptides, Cyclic; Rabbits; Sulfonamides; Uveitis | 2018 |
Blockade of endothelin receptors reduces tumor-induced ongoing pain and evoked hypersensitivity in a rat model of facial carcinoma induced pain.
Topics: Animals; Bosentan; Cancer Pain; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelin Receptor Antagonists; Facial Neoplasms; Hyperalgesia; Male; Morphine; Rats; Rats, Wistar; Receptors, Endothelin; Sulfonamides | 2018 |
Novel propyl karaya gum nanogels for bosentan: In vitro and in vivo drug delivery performance.
Topics: Animals; Antihypertensive Agents; Bosentan; Calorimetry, Differential Scanning; Disease Models, Animal; Drug Delivery Systems; Drug Liberation; Hypertension; Karaya Gum; Male; Mice; Nanogels; Polyethylene Glycols; Polyethyleneimine; Rats, Wistar; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2019 |
Using bosentan to treat paraquat poisoning-induced acute lung injury in rats.
Topics: Acute Lung Injury; Alveolar Epithelial Cells; Animals; Bosentan; Disease Models, Animal; Endothelin-1; Hydroxyproline; Male; Paraquat; Rats; Rats, Wistar; Sulfonamides; Transforming Growth Factor beta1 | 2013 |
Bosentan reduces neuronal apoptosis following spinal cord ischemic reperfusion injury.
Topics: Animals; Apoptosis; Bosentan; Brain Ischemia; Disease Models, Animal; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spinal Cord; Spinal Cord Injuries; Sulfonamides | 2014 |
Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Pyrimidines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Sulfonamides | 2014 |
Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Pulmonary Artery; Quinolines; Rats; Rats, Wistar; Sulfonamides; Urea; Urotensins | 2014 |
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Topics: Animals; Bosentan; Chromatin Immunoprecipitation; Collagen Type I; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibroblasts; Fibrosis; Humans; Immunoblotting; Mice; Phenotype; Proto-Oncogene Protein c-fli-1; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Systemic; Signal Transduction; Skin; Sulfonamides | 2014 |
Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Inflammation; Male; Monocrotaline; Rats; Rats, Wistar; Sulfonamides | 2014 |
The ocular endothelin system: a novel target for the treatment of endotoxin-induced uveitis with bosentan.
Topics: Animals; Aqueous Humor; Bosentan; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelins; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucocorticoids; Male; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Endothelin; RNA; Sulfonamides; Treatment Outcome; Uveitis | 2014 |
Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma.
Topics: Animals; Astrocytes; Bosentan; Complement C1q; Disease Models, Animal; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin-2; Glaucoma; Humans; Mice; Mice, Inbred DBA; Nerve Degeneration; Pyrimidines; Receptor, Endothelin A; Retinal Ganglion Cells; Sulfonamides | 2014 |
Bosentan protects the spinal cord from ischemia reperfusion injury in rats through vascular endothelial growth factor receptors.
Topics: Animals; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Ischemia; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spinal Cord Injuries; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
What is the role of bosentan in healing of femur fractures in a rat model?
Topics: Animals; Bony Callus; Bosentan; Disease Models, Animal; Femoral Fractures; Femur; Fracture Healing; Male; Rats; Rats, Wistar; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography.
Topics: Animals; Blood Pressure; Bosentan; Cardiography, Impedance; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2014 |
Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity.
Topics: Animals; Bosentan; Cefmetazole; Chemical and Drug Induced Liver Injury; Cholestasis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ganciclovir; Hepatocytes; Humans; Metabolic Clearance Rate; Mice, Transgenic; Species Specificity; Sulfonamides; Thymidine Kinase; Tissue Distribution; Transgenes | 2015 |
Antenatal use of bosentan and/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia.
Topics: Animals; Bosentan; Disease Models, Animal; Female; Hernias, Diaphragmatic, Congenital; Lung; Lung Diseases; Phenyl Ethers; Piperazines; Pregnancy; Purines; Random Allocation; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Vascular Remodeling | 2014 |
Altered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia.
Topics: Animals; Bosentan; Catalase; Cell Proliferation; Coculture Techniques; Disease Models, Animal; Endothelial Cells; Endothelin-1; Hernias, Diaphragmatic, Congenital; Myocytes, Smooth Muscle; Pulmonary Artery; Reactive Oxygen Species; RNA, Small Interfering; Sheep; Signal Transduction; Sulfonamides; Superoxide Dismutase | 2015 |
Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.
Topics: Actins; Animals; Anti-Inflammatory Agents; Bleomycin; Bosentan; Catalase; Collagen Type I; Collagen Type II; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Lung; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Oxidative Stress; Peroxidase; Pneumonia; Pulmonary Edema; RNA, Messenger; Sulfonamides; Superoxide Dismutase; Time Factors | 2015 |
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Pulmonary Artery; Pyrimidines; Rats, Wistar; Sulfonamides; Time Factors; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2015 |
The role of endothelin-1 and endothelin receptor antagonists in allergic rhinitis inflammation: ovalbumin-induced rat model.
Topics: Animals; Bosentan; Disease Models, Animal; Down-Regulation; Endothelin Receptor Antagonists; Endothelin-1; Female; Immunoglobulin E; Loratadine; Ovalbumin; Rats, Sprague-Dawley; Rhinitis, Allergic; RNA, Messenger; Sulfonamides; Tumor Necrosis Factor-alpha | 2016 |
Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.
Topics: Animals; Bosentan; Collateral Circulation; Cyclooxygenase 2; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Hypertension, Portal; Liver Cirrhosis; Male; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Phenylpropionates; Phosphoproteins; Portal Pressure; Proto-Oncogene Proteins c-akt; Pyridazines; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1.
Topics: Acetylcholine; Animals; Bosentan; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Prostaglandins; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Vasodilation; Vasodilator Agents | 2008 |
Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output, Low; Coxsackievirus Infections; Disease Models, Animal; Endothelin A Receptor Antagonists; Enterovirus B, Human; Enzyme Activation; Humans; Mice; Myocarditis; p38 Mitogen-Activated Protein Kinases; Stroke Volume; Sulfonamides; Viral Load | 2009 |
The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Topics: Animals; Bosentan; Connexin 43; Disease Models, Animal; Endothelin Receptor Antagonists; Gap Junctions; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Microscopy, Confocal; Microscopy, Electron; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling | 2009 |
Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin-1; Genetic Predisposition to Disease; Heart; Hypertension; Hypoxia; Hypoxia-Inducible Factor 1; Male; Myocardial Infarction; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sleep Apnea, Obstructive; Sulfonamides | 2009 |
Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.
Topics: Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Basement Membrane; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Hypertension; Male; Membrane Proteins; Metalloendopeptidases; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Retinal Diseases; Retinal Vessels; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2010 |
Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Topics: Analysis of Variance; Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Bleomycin; Bosentan; Collagen; Connective Tissue Growth Factor; Disease Models, Animal; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Physical Conditioning, Animal; Pulmonary Fibrosis; Rats; Rats, Wistar; Sulfonamides; Time Factors | 2010 |
Role of endothelin receptors in the control of central nervous system parasitism in Trypanosoma cruzi infection in rats.
Topics: Animals; Antihypertensive Agents; Antiparasitic Agents; Bosentan; Brain; Chagas Disease; Cytokines; Disease Models, Animal; Encephalitis; Endothelin Receptor Antagonists; Endothelins; Immunity, Innate; Male; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Treatment Outcome; Trypanosoma cruzi; Up-Regulation | 2010 |
Effect of pravastatin on ventricular arrhythmias in infarcted rats: role of connexin43.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Connexin 43; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Maleimides; Mevalonic Acid; Myocardial Infarction; Myocardium; Pravastatin; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Wistar; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Time Factors; Ultrasonography | 2010 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Genes, Reporter; Hemodynamics; Hyperoxia; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Transgenic; NFATC Transcription Factors; Promoter Regions, Genetic; Protein Kinase Inhibitors; Receptor, Endothelin A; rho-Associated Kinases; Sulfonamides; Time Factors | 2010 |
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Echocardiography; Endothelin Receptor Antagonists; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Lung; Myocardial Infarction; Prognosis; Rats; Sulfonamides | 2011 |
Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression; Hemodynamics; Hepatic Stellate Cells; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Oligopeptides; Peptides, Cyclic; Piperidines; Portal Pressure; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Regional Blood Flow; Sulfonamides | 2010 |
The rise and fall of endothelin receptor antagonists in congestive heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiology; Disease Models, Animal; Endothelin Receptor Antagonists; Heart; Heart Failure; Humans; Hypertension, Pulmonary; Myocardium; Prognosis; Sulfonamides | 2011 |
Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma.
Topics: Animals; Bosentan; Cluster Analysis; Complement C1q; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-2; Female; Gene Expression Profiling; Glaucoma; Humans; Mice; Mice, Inbred DBA; Mice, Mutant Strains; Optic Nerve; Retina; Signal Transduction; Sulfonamides; Up-Regulation | 2011 |
Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Collagen; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Myocardium; Protein Isoforms; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |
Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthralgia; Arthritis, Experimental; Bosentan; Disease Models, Animal; Edema; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Female; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Nociception; Phenylpropionates; Pyridazines; Secondary Prevention; Sulfonamides | 2011 |
Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Female; Hypertension, Pulmonary; Nitrates; Nitrosation; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sulfonamides | 2013 |
Endothelin ET(B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice.
Topics: Acute Disease; Analysis of Variance; Animals; Atrasentan; Bosentan; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Evans Blue; Lung; Male; Mice; Mice, Inbred Strains; Neutrophil Infiltration; Oleic Acid; Pyrimidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Respiratory Distress Syndrome; Sulfonamides | 2002 |
Altered myocardial thin-filament function in the failing Dahl salt-sensitive rat heart: amelioration by endothelin blockade.
Topics: Actin Cytoskeleton; Animals; Bosentan; Calcium; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Male; Muscle, Skeletal; Myocardial Contraction; Myocardium; Myofibrils; Phosphorylation; Protein Isoforms; Protein Kinase C; Rats; Rats, Inbred Dahl; Signal Transduction; Sulfonamides; Troponin T | 2003 |
Chronic endothelin antagonism restores cerebrovascular function in diabetes.
Topics: Animals; Antihypertensive Agents; Bosentan; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Male; Middle Cerebral Artery; Muscle Development; Potassium Channels; Rats; Rats, Wistar; Receptors, Endothelin; Recovery of Function; Sulfonamides; Vasodilation | 2003 |
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; Bosentan; Cardiomyopathies; Dansyl Compounds; Disease Models, Animal; Endothelin-1; Fibrosis; Hypertension; Irbesartan; Male; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cell Surface; Sulfonamides; Tetrazoles; Time Factors; Vasoconstrictor Agents | 2003 |
Endothelin receptor blockade in canine oleic acid-induced lung injury.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Infusions, Intravenous; Oleic Acid; Prospective Studies; Pulmonary Circulation; Pulmonary Gas Exchange; Pulmonary Wedge Pressure; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Respiratory Distress Syndrome; Sulfonamides; Vascular Resistance | 2003 |
Effects of bosentan on neointimal response following coronary angioplasty.
Topics: Administration, Oral; Angioplasty; Animals; Antihypertensive Agents; Bosentan; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Immunohistochemistry; Sulfonamides; Swine; Tunica Intima | 2003 |
Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Bosentan; Calcium Channels, T-Type; Cells, Cultured; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sulfonamides | 2003 |
Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock.
Topics: Animals; Antihypertensive Agents; Bosentan; Cecum; Disease Models, Animal; Endothelin Receptor Antagonists; Kidney; Ligation; Liver; Mice; Shock, Septic; Sodium Chloride; Spleen; Sulfonamides; Survival Rate; Time Factors; Wounds and Injuries | 2004 |
Bosentan preserves endothelial function in mice overexpressing APP.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Mice; Mice, Inbred C57BL; Mice, Transgenic; Sulfonamides; Vasodilation | 2006 |
Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bosentan; Cell Adhesion; Disease Models, Animal; Endothelin Receptor Antagonists; Female; Inflammatory Bowel Diseases; Leukocytes; Mice; Mice, Inbred BALB C; Severity of Illness Index; Sulfonamides | 2006 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis.
Topics: Alanine Transaminase; Animals; Antihypertensive Agents; Bosentan; Cyclooxygenase 2; Disease Models, Animal; DNA Primers; Endothelins; Endotoxins; Gene Expression Regulation, Enzymologic; Lipopolysaccharides; Liver; Liver Cirrhosis, Experimental; Male; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2006 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold Temperature; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin-1; Endothelins; Grooming; Hyperalgesia; Indomethacin; Male; Maxillary Nerve; Nerve Compression Syndromes; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Trigeminal Neuralgia | 2006 |
[Intestinal blood flow alterations in postoperative intraabdominal adhesion formation and the role of Endothelin-1 blockade].
Topics: Abdomen; Animals; Antihypertensive Agents; Blood Flow Velocity; Bosentan; Disease Models, Animal; Endothelin-1; Intestines; Mesenteric Arteries; Peritoneal Diseases; Postoperative Complications; Pulsatile Flow; Rats; Rats, Wistar; Sulfonamides; Tissue Adhesions | 2006 |
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
Blockade of endothelin ET(A)/ET(B) receptors favors a role for endothelin during acute Trypanosoma cruzi infection in rats.
Topics: Animal Structures; Animals; Bosentan; Chagas Disease; Chemokines; Cytokines; Diaphragm; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Male; Myocardium; Nitrates; Nitrites; Parasitemia; Rats; Sulfonamides; Trypanosoma cruzi | 2006 |
Endothelin-1 receptors play a minor role in the protection against acute Trypanosoma cruzi infection in mice.
Topics: Acute Disease; Animals; Bosentan; Chagas Cardiomyopathy; Cytokines; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Male; Mice; Mice, Inbred C57BL; Parasitemia; Sulfonamides; Trypanosoma cruzi | 2007 |
Physiological concentration of 17beta-estradiol on sympathetic reinnervation in ovariectomized infarcted rats.
Topics: Animals; Bosentan; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Estrogens; Female; GAP-43 Protein; Myocardial Infarction; Nerve Growth Factor; Nerve Regeneration; Norepinephrine; Ovariectomy; Rats; Rats, Wistar; Sulfonamides; Sympathetic Nervous System; Tamoxifen; Tyrosine 3-Monooxygenase | 2008 |
Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bosentan; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Emphysema; Endothelin Receptor Antagonists; Inflammation Mediators; Lung; Male; Pancreatic Elastase; Rats; Rats, Wistar; Sulfonamides | 2007 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; GAP-43 Protein; Hemodynamics; Hydralazine; Immunohistochemistry; Male; Methoxyhydroxyphenylglycol; Myocardial Infarction; Myocardium; Nerve Growth Factor; Neurofilament Proteins; Norepinephrine; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease.
Topics: Anemia, Sickle Cell; Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Humans; Hypoxia; Kidney; Lung; Mice; Mice, Inbred C57BL; Neutrophils; Receptors, Endothelin; Regional Blood Flow; Renal Circulation; Sulfonamides; Vasoconstriction | 2008 |
The effects of endothelin receptor blockade by bosentan on the healing of a bowel anastomosis in an experimental Crohn's disease model.
Topics: Anastomosis, Surgical; Animals; Antihypertensive Agents; Bosentan; Crohn Disease; Disease Models, Animal; Endothelin Receptor Antagonists; Jejunum; Male; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Treatment Outcome; Wound Healing | 2008 |
Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Bosentan; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Heart Rate; Injections, Intravenous; Laser-Doppler Flowmetry; Male; Neural Conduction; Rats; Rats, Wistar; Sciatic Nerve; Streptozocin; Sulfonamides | 1995 |
Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat.
Topics: Animals; Blood Vessels; Bosentan; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Electrocardiography; Endothelins; Heart; Male; Myocardial Ischemia; Permeability; Rats; Rats, Wistar; Sulfonamides | 1995 |
The role of endothelin in experimental cerebral vasospasm.
Topics: Animals; Basilar Artery; Bosentan; Cerebral Angiography; Disease Models, Animal; Dogs; Endothelin Receptor Antagonists; Endothelins; In Vitro Techniques; Ischemic Attack, Transient; Muscle, Smooth, Vascular; Rabbits; Receptors, Endothelin; Subarachnoid Hemorrhage; Sulfonamides; Time Factors | 1995 |
Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.
Topics: Analysis of Variance; Animals; Blotting, Northern; Bosentan; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Gene Expression Regulation; Humans; Kidney; Kidney Diseases; Male; Nephrectomy; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Sulfonamides | 1996 |
An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis.
Topics: Animals; Antibody Specificity; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Glomerulonephritis, Membranoproliferative; Immunohistochemistry; In Situ Hybridization; Kidney; Kidney Function Tests; Protein Precursors; Proteinuria; Rats; Rats, Wistar; Receptor, Endothelin A; Receptors, Endothelin; RNA, Messenger; Sulfonamides | 1996 |
An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis.
Topics: Administration, Oral; Animals; Bosentan; Colitis; Colon; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Male; Rats; Rats, Sprague-Dawley; Sulfonamides | 1996 |
Bosentan improves renal regional blood flow in rats with experimental congestive heart failure.
Topics: Animals; Bosentan; Disease Models, Animal; Heart Failure; Kidney; Male; Rats; Rats, Wistar; Regional Blood Flow; Sulfonamides | 1996 |
[Bosentan attenuates the hypertensive effect of angiotensin II in rats].
Topics: Angiotensin II; Animals; Blood Pressure; Bosentan; Disease Models, Animal; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Hemodynamics; Hypertension; Male; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Renal Circulation; Sulfonamides | 1997 |
Renal endothelin system in polycystic kidney disease.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Binding, Competitive; Bosentan; Culture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Glomerular Filtration Rate; Immunohistochemistry; Male; Polycystic Kidney Diseases; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Reference Values; Renal Circulation; Sulfonamides | 1998 |
Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Bosentan; Disease Models, Animal; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Renovascular; Infusions, Intravenous; Losartan; Radioimmunoassay; Receptor, Endothelin A; Sulfonamides; Vascular Resistance | 1998 |
Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists.
Topics: Animals; Antihypertensive Agents; Arthritis, Reactive; Bosentan; Carrageenan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Excipients; Knee Joint; Lipopolysaccharides; Male; Nociceptors; Oligopeptides; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Sulfonamides; Vasoconstrictor Agents; Viper Venoms | 1998 |
Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.
Topics: Administration, Oral; Animals; Atrasentan; Bosentan; Coronary Vessels; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Hemodynamics; Hypercholesterolemia; Pyrrolidines; Random Allocation; Receptor, Endothelin A; Sulfonamides; Swine | 1999 |
Protective effect of the endothelin antagonist Bosentan against ischemic skeletal muscle necrosis.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Laser-Doppler Flowmetry; Leukocyte Count; Male; Muscle, Skeletal; Necrosis; Neutrophils; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Time Factors | 1999 |
Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan.
Topics: Adrenocorticotropic Hormone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bosentan; Disease Models, Animal; Eating; Endothelin Receptor Antagonists; Hypertension; Male; Quality Control; Rats; Rats, Sprague-Dawley; Sulfonamides; Water | 1999 |
Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist.
Topics: Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Bosentan; Cardiovirus Infections; Disease Models, Animal; Encephalomyocarditis virus; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Heart; Male; Metalloendopeptidases; Mice; Mice, Inbred DBA; Myocarditis; Myocardium; Protein Precursors; RNA, Messenger; Sulfonamides | 1999 |
[Effects of endothelin antagonists on isolated perfused murine livers in the early phase of warm ischemia-reperfusion injury under propofol anesthesia].
Topics: Anesthesia, Intravenous; Anesthetics, Intravenous; Animals; Azepines; Bosentan; Disease Models, Animal; Endothelins; Free Radical Scavengers; In Vitro Techniques; Liver; Male; Oligopeptides; Piperidines; Propofol; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sulfonamides | 1999 |
Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis.
Topics: Animals; Bosentan; Brain; Cell Count; Cerebrovascular Circulation; Disease Models, Animal; Endothelin-1; Female; Male; Meningitis, Pneumococcal; Neuroprotective Agents; Rats; Rats, Wistar; Sulfonamides | 2000 |
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Bosentan; Chronic Disease; Culture Techniques; Disease Models, Animal; Dogs; Endothelin-1; Female; Hemodynamics; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; Probability; Pulmonary Artery; Pulmonary Circulation; Pulmonary Embolism; Reference Values; Sulfonamides; Tomography, Emission-Computed; Vascular Resistance | 2000 |
The timing of endothelin and nitric oxide inhibition affects survival in a mice model of septic shock.
Topics: Animals; Antihypertensive Agents; Bosentan; Canavanine; Disease Models, Animal; Endothelin Receptor Antagonists; Endotoxins; Enzyme Inhibitors; Guanidines; Lipopolysaccharides; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Shock, Septic; Sulfonamides; Survival Rate | 2001 |
Pharmacological regulation of postischemic sinusoidal diameters in rats--a new approach for reducing hepatic ischemia/reperfusion injury.
Topics: Animals; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Ischemia; Liver; Microcirculation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Vasoconstriction | 2001 |
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bosentan; Cilazapril; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelins; Hypertension; Kidney; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sulfonamides | 2002 |
Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia in rats.
Topics: Animals; Apoptosis; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Failure; Male; Myocardial Ischemia; Myocardium; Rats; Rats, Wistar; Sulfonamides; Ventricular Remodeling | 2002 |
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Biphenyl Compounds; Bosentan; Calcium Channel Blockers; Collagen; Dansyl Compounds; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Immunohistochemistry; Irbesartan; Male; Muscle, Smooth, Vascular; Nifedipine; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles | 2002 |